With Its R&D On Track, GSK R&D Chair Slaoui Cites Individual Responsibility, Culture As Success Factors
This article was originally published in The Pink Sheet Daily
Executive Summary
The Big Pharma did notably fewer deals in 2011, largely because of stringent criteria, reined in by a tight budget for R&D, but also because of its recent interest in external venture capital partners, some of which are not disclosed to the public.
You may also be interested in...
Verastem Joins The Public Markets With A Strong IPO
Verastem IPO’d at $10 per share on Jan. 26, despite having only preclinical assets in its pipeline. Strong interest from large companies for cancer stem cell therapies helped contribute to the price.
GlaxoSmithKline R&D Under Scrutiny In Bid For Fresh Funding
It's crunch time for GlaxoSmithKline PLC's 38 biotech-like R&D units, which are competing for further funding as they reach the end of their first three-year investment cycle.
Financings Of The Fortnight: Corporate Venture Is Here To Stay
Private funding rounds involving corporate venture tend to be much richer in the biotech arena, a recent review indicates.